Table 1.

Study and patient characteristics

				Sample size
Study	Therapy in experimental group	Therapy in control group	Country	Experimental	Control	Duration of treatment	Inclusion population
Itoh et al. 21	Silodosin 8 mg daily	Tlacebo	Japan	56	56	4 weeks	male patients with symptomatic calculi and had unilateral distal ureteral calculi of less than 10 mm in diameter
Rathi et al. 23	Silodosin 8 mg daily	Placebo	India	29	28	4 weeks	patients with symptomatic calculi and had unilateral distal ureteral calculi of less than 10 mm in diameter
Rathi et al. 23	Silodosin 8 mg daily	Tamsulosin 0.4 mg daily	India	29	30	4 weeks	Patients with symptomatic calculi and had unilateral distal ureteral calculi of less than 10 mm in diameter
Kumar et al. 5	Silodosin 8 mg daily	Tamsulosin 0.4 mg daily	India	90	90	4 weeks	Patients aged ≥ 18 years with a ureteral stone of 5‐10mmin size situated below the common iliac vessels
Imperatore et al. 20	Silodosin 8 mg daily	Tamsulosin 0.4 mg daily	Italy	50	50	4 weeks	Aged ≥ 18 years with a single, unilateral, symptomatic, distal ureteric stone of 10 mm or smaller
Itoh et al. 22	Silodosin 8 mg daily	Placebo	Japan	95	92	8 weeks	Patients with unilateral ureteral calculi of less than 10 mm in diameter
Gupta et al. [24]	Silodosin 8 mg daily	Tamsulosin 0.4 mg daily	India	50	50	4 weeks	Patients unilateral, non–impacted, uncomplicated middle or lower ureteral stones which were </= 1 cm
Sur et al. 25	Silodosin 8 mg daily	Placebo	USA	115	117	4 weeks	Patients aged ≥18 years with a unilateral calculus ≥4 mm and ≤10 mm in any location of the ureter visible within 7 d
Dell'Atti et al. 26	Silodosin 8 mg daily	Tamsulosin 0.4 mg daily	Italy	66	67	3 weeks	Patients with renal colic, a single, unilateral, radiopaque, distal ureteral stone (range 4–10 mm in size)